USING TARGETED THERAPIES FOR INFLAMMATORY DERMATOSES
Introduction
Targeted therapies continue to revolutionize the way we manage chronic inflammatory diseases in dermatology. In contrast to conventional immunosuppressive agents such as methotrexate, cyclosporine, and azathioprine, targeted therapies have the advantage of reducing inflammation to improve cutaneous disease while diminishing the concerns of cumulative end-organ toxicity. This has led to a paradigm shift from approaching disease management from a primarily as-needed basis to the goal of achieving continuous control. Nowhere in dermatology is this transformation more evident than in the treatment of psoriasis
Introduction
Targeted therapies continue to revolutionize the way we manage chronic inflammatory diseases in dermatology. In contrast to conventional immunosuppressive agents such as methotrexate, cyclosporine, and azathioprine, targeted therapies have the advantage of reducing inflammation to improve cutaneous disease while diminishing the concerns of cumulative end-organ toxicity.
TNF inhibitors for psoriasis
Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating cutaneous inflammation in the pathogenesis of psoriasis.
Ustekinumab for the treatment of psoriasis: an evidence update
We review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis.
IL-17 inhibitors for psoriasis
The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis.
IL-23 inhibitors for moderate-to-severe psoriasis
Since the identification of high levels of interleukin 23 (IL-23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit.